Since the World Health Organization declared it a pandemic on March 11, 2020, the COVID-19 coronavirus—the greatest global public health emergency in a century—has disrupted or delayed many aspects of life, including cancer care. But it’s also opened new opportunities for nursing innovation and brought much-needed change to health care. Here’s where we are one year later.
Watching patients—or even colleagues—suffer or die, not being able to protect yourself with the right personal protective equipment, worry about exposing loved ones, and the challenge of balancing it all contribute to an immeasurable psychological burden for nurses and other healthcare professionals during a pandemic. Studies show that the effects are serious, leading to post-traumatic stress, anxiety, depression, and, in some cases, suicide among providers.
Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.
Three years ago, Tony, a 42-year-old man, began FOLFOX chemotherapy treatment for stage III colon cancer and achieved a complete response. Two years later, a biopsy of an intraabdominal lesion uncovered metastatic disease, and he was prescribed the epidermal growth factor inhibitor (EGFRi) cetuximab. Alex, the oncology nurse educating Tony on the side effects of EGFRi therapy, understands that skin toxicities are common with the class of drugs and looks for national guidelines for prevention and management direction.